Course Title: 2012 Psychiatry CME To Go Audio Lecture Series

Transcription

1 American Physician Institute for Advanced Professional Studies, LLC Course Title: 2012 Psychiatry CME To Go Audio Lecture Series Intended Audience: Psychiatrists CME Accreditation and Designation Statement Accreditation Statement: This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of PeerPoint Medical Education Institute, LLC and American Physician Institute for Advanced Professional Studies, LLC. PeerPoint Medical Education Institute, LLC is accredited by the ACCME to sponsor continuing medical education for physicians. The American Board of Psychiatry and Neurology has reviewed the Psychiatry CME To Go Audio Lecture Series and has approved this program as part of a comprehensive Self Assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification. Designation Statement: PeerPoint Medical Education Institute, LLC designates this educational activity for a maximum of 32 AMA PRA Category 1 credits and 8 ABPN Self Assessment credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. This CME activity was planned and produced in accordance with the ACCME Essentials. Faculty Financial Disclosures Dr. Damion Grasso has no financial interest or affiliation to disclose. Christopher Pittenger has served as a consultant for Hoffman LaRoche Pharmaceuticals. Victoria Hendrick has no financial interest or affiliation to disclose. Dawn Velligan has received research support from Janssen Pharmaceuticals and has served as a consultant for Janssen, Merck, Hoffman LaRoche, Abbott, Teva, GenTek and Takeda Pharmaceuticals. Francis Mondimore has no financial interest or affiliation to disclose. Stephen Levine has received research support from Biosante, Palatia, and Endoceutics Pharmaceuticals. Frank Tarazi has received research support from Forest Labs, Novartis and has served as a consultant for Merck Pharmaceuticals. Deirdre Conroy has no financial interest or affiliation to disclose. 1

2 Learning Objectives Volume One: Topic 1: Update on Pharmacological Treatment of Acute Stress and Post Traumatic Stress Disorders 1. Identify new outcomes of Acute Stress and Post Traumatic Stress Disorder 2. Assess different approaches of pharmacotherapy for different symptoms 3. Consider new and effective psychotherapeutic approaches for patients Topic 2: Treatment Resistant Obsessive Compulsive Disorder - More Options than You Think 1. Identify the symptom presentation, etiology and assessments of treatment resistant OCD 2. Recommend medications effective for OCD in patients 3. Summarize somatic treatments proven effective for OCD Topic 3: Bipolar Disorder in Pregnancy: Reviewing Treatment Options 1. Recommend best medications for treatment for patients with bipolar depression during pregnancy 2. Differentiate developmental outcomes based on exposure to antidepressants during pregnancy 3. Identify best natural treatments for bipolar disorder during pregnancy Topic 4: Treating Cognitive Symptoms in Schizophrenia- Is there reason for hope? 1. Define the cognitive impact of schizophrenia 2. Examine the efficiency of atypical antipsychotics on cognitive symptoms for patients with schizophrenia 3. Assess novel treatments for patients to improve cognitive symptoms in schizophrenia Topic 5: Chronic Depression: Reviewing Treatment Options 1. Define the four Symptom levels of depressive illness 2. Assess possible treatment options for patients with chronic depression 3. Formulate novel pharmacotherapeutic approaches to treat chronic depression Topic 6: Update on Male Sexual Disorders: Erectile Dysfunction and Premature Ejaculation 1. Examine the pharmacology of medication options for erectile dysfunction 2. Consider the role of psychiatrist in evaluating male sexual disorders 3. Describe pharmacologic and psychotherapeutic approaches for treating male sexual disorders Topic 7: A comparison of the three newest SGA s on the market- Asenapine, Iloperidone, and Lurasidone 1. Define the indications, pharmacokinetics, efficacy and dosing of Asenapine 2. List the appropriate dosing, side effects and efficacy in Iloperidone 3. Identify indications, receptor profile and pharmacokinetics of Lurasidone 2

3 Topic 8: Treating Insomnia in Special Populations: The Elderly, the Chronic Hypnotic User and the Substance Abuser 1. Recognize treatment options for patients with insomnia 2. Summarize methods to manage insomnia in the elderly, patients on hypnotic medication and substance abusers 3. Complete insomnia diagnosis and assessment Volume Two: Topic 9: The Antidepressant Use in Bipolar Disorder: the good, the bad and the unknown 1. Identify the efficacy of antidepressants for treatment of acute bipolar depression in patients 2. Validate the efficacy of antidepressant use in prevention of bipolar depression 3. Contrast the risks and benefits of antidepressant use in bipolar disorder Topic 10: Update on Dementia Assessment and Treatment 1. Identify new findings on Alzheimer s disease, cerebrovascular disease and Lewy Body Disease 2. Recommend new medications and formulations for dementia patients 3. Summarize the new category of FDA approved Intervention Topic 11: Complementary and Alternative Treatments in Major Depressive Disorder. What you don t know can hurt you. 1. List the review mechanism of action, evidence in depression and side effects of Omega- 3 fatty acids 2. Identify the evidence in depression and drug interactions of St. Johns wort 3. Define the side effects and evidence in depression of folic acid Topic 12: Treating Comorbid Bipolar Disorder and Substance Abuse: 1. Identify the scope of comorbid bipolar disorder and substance abuse 2. Summarize the impact of substance abuse on bipolar disorder outcomes 3. Recommend practical management options for a substance-abusing bipolar patient Topic 13: Adult ADHD: Emerging Treatment Findings with Practical Management Advice 1. Recognize the scope of ADHD in adults 2. Contrast guidelines for stimulant and non-stimulant medications 3. Define stimulant medication diversion among patients Topic 14: A forgotten (and formidable) class- A review of the MAOI s in the treatment of depression and anxiety 1. Apply the practical uses of MAOI s for patients with depression and anxiety 2. Validate the use of MAOI s in affective and anxiety disorders 3. Assess the use of MAOIs for the treatment of mood disorders 3

4 Topic 15: Update on the Pharmacotherapy of Alcohol Dependence 1. Examine alcohol withdrawal protocol 2. Explain the role of pharmacotherapy in managing sobriety 3. Reflect which patients may benefit from which medication Topic 16: Review and Comparison of the New Somatic Therapies- TMS, VNS, DBS 1. Describe the use of Transcranial Magnetic Stimulation 2. Differentiate between Vagal Nerve Stimulation and Deep Brain Stimulation 3. Integrate new somatic treatments into your practice Volume Three: Topic 17: Psychotherapeutic Approaches to Treating the Borderline Personality Disorder Patient When Intensive Programs are Unavailable 1. Assess the evidence base for efficacy of psychotherapy in borderline personality disorder treatment 2. Integrate psychotherapy for Borderline Personality Disorder when intensive treatment programs are unavailable 3. Recommend practical advice for patients with BPD during medication administration appointments Topic 18: Psychopharmacology of Treatment Resistant Depression- 1. Define causes of treatment resistant depression 2. Identify medications for patients with treatment resistant depression 3. Apply other somatic treatments effective for treatment resistant depression in patients Topic 19: Review of Relevant Medical- Legal Issues in Managing Patients with Dementia or Other Cognitive Dysfunction 1. Recognize important issues for patients with cognitive decline 2. Explaining the importance of informed consent, power of attorney and guardianship to patients suffering cognitive dysfunction 3. Validate the role and limits of the treating psychiatrist Topic 20: Cognitive Dysfunction in Schizophrenia: the Overlooked Core Symptom 1. Recognize symptoms of Schizophrenia 2. Examine possible treatment options for patients with schizophrenia 3. Identify the role of cognitive impairments in schizophrenia Topic 21: Depression and Comorbid Anxiety: An overview of Pharmacological Options 1. Recognize the scope of comorbid anxiety and depression 2. Rank different pharmacotherapy approaches for different approaches 3. Measure which pharmacotherapies are preferred for treating depressed and anxious patients 4

5 Topic 22: Treatment Non Adherence: How to recognize it, how to measure it, how to improve it 1. Define the scope of non-adherence among different patient populations 2. Classify types of non-adherence 3. Assemble practical management options to improve treatment adherence Topic 23: Supercharging Your Med Administration Sessions: Incorporating Fast and Highly Effective Psychotherapeutic Interventions 1. Formulate guidelines for your treatment interventions 2. Describe to patients their vulnerability factors and acute triggers 3. Integrate fast problem- solving therapies techniques into your practice Topic 24: Update on the treatment of acute agitation in psychosis- Should SGA s be the first line pharmacological treatment? 1. Identify acute agitation in psychotic patients 2. Differentiate the efficacy of FGAs or SGAs for use in acute agitation 3. Apply a personal evidence-based algorithm for management of patients with acute agitation Volume Four: Topic 25: Management of treatment resistant schizophrenia- what to do when standard treatments fails 1. List conventional antipsychotics and their outcomes in patients 2. Critique novel antipsychotics use in treatment resistant schizophrenia 3. Describe non pharmacologic augmentation strategies for schizophrenia Topic 26: Treatment Resistant Anxiety- the Current Thinking from a Biological and Psychological Standpoint 1. Define treatment resistant anxiety 2. Assess novel antipsychotics in treatment resistant anxiety for your patients 3. Summarize the challenges in treating resistant disorders Topic 27: Effective Incorporation of Psychotherapy into the Patients Treatment 1. Contrast the major Psychotherapeutic Approaches 2. Explain the effectiveness of psychotherapy in current practice 3. Assess the role of the psychiatrist in recommending and monitoring psychotherapy administered by a different clinician Topic 28: Metabolic Syndrome with SGA s- What we know now, your options in managing it, and its potential medical-legal ramifications 1. Identify the components of metabolic syndrome 2. Formulate guidelines for monitoring and managing metabolic syndrome in patients 3. Consider treatment options to prevent metabolic syndrome 5

6 Topic 29: Role of Pharmacogenomics Tests in Guiding Clinical Decision-Making 1. Judge where psychiatrist are today in the clinical application on pharmacogenomics tests 2. Assess commercially available pharmacogenomics tests for psychiatry 3. Integrate pharmacogenomics tests into your practice Topic 30: Dependent Personality Disorder: Diagnostic and Treatment Update 1. Recognize dependent personality disorder in patients 2. Identify dependent personality traits 3. Summarize the role of medications in managing dependent personality disorder Topic 31: Social Anxiety Disorder- An Update on Evidence-Based Treatment Options 1. Examine the scope of social anxiety disorder 2. Recommend evidence based treatment options for patients with social anxiety disorder 3. Formulate practical prescribing guidance for medications to patients with social anxiety disorder Topic 32: Traumatic Brain Injury 1. Estimating the scope of Traumatic brain injury in different patient populations 2. Assess immediate management steps directly following traumatic brain injury 3. Assemble practical prescribing guidelines for effective medications for patients with traumatic brain injury 6